CorMedix to Participate in Upcoming Investor Conferences

Core Insights - CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions [2] - The company will participate in investor meetings at upcoming conferences in September 2025 [1] Company Overview - CorMedix's lead product, DefenCath (taurolidine and heparin), was approved by the FDA on November 15, 2023 [2] - The commercial launch of DefenCath began in inpatient settings in April 2024 and in outpatient settings in July 2024 [2] - In 2025, CorMedix commenced clinical studies for Total Parenteral Nutrition and Pediatric patient populations, with plans to develop DefenCath as a catheter lock solution for other patient populations [2]